Skip to main content
Premium Trial:

Request an Annual Quote

Caris Life Sciences Caris Discovery

Caris Life Sciences has expanded its Caris Discovery platform, a proprietary, multi-omics target discovery engine designed to unlock otherwise inaccessible drug targets in areas of high unmet clinical need.

The firm said the approach relies on what it calls the ADAPT biotargeting system, which deploys an unbiased library of single-strand DNA aptamers that bind to molecular targets in patient tissue samples. Identified targets are then validated and characterized for their disease and biological relevance via gene expression profiling, epitope mapping, functional screening, phenotypic analyses, and in vitro model systems.

The Scan

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.

Neurological Outcomes Linked to Innate Immune Features After Cardiac Arrest

Researchers reporting in Med dig into immune features found a few hours after cardiac arrest that correspond with neurological outcomes.

Mouse Study Finds Circadian Rhythm-Related Gene Expression Changes Linked to Sleep Apnea

A paper in PLOS Biology reveals tissue-specific circadian rhythm and gene expression patterns in an intermittent hypoxia-based mouse model of obstructive sleep apnea.

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.